Interview with Bingshen Li, CEO, SinoGenoMax
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Address: No. 3-707 North Yongchang Road,BDA,Beijing 100176,P.R.China.,China
Tel: +86 10 6788 3332
Web: http://www.sinogenomax.com/en
As one of the largest genomics-based biotech companies in China, SinoGenoMax Co.,Ltd. was incorporated in September 1998 by a joint investment from the Beijing Municipal Science & Technology Commission and Beijing Boda Sci-Tech Venture Capital Ltd. Its founding members include the Chinese Academy of Medical Sciences, Peking University, the Chinese Academy of Science, and the Beijing Institute of Medical Sciences. The affililated institute, Chinese National Human Genome Center of Beijing (CHGB) was established in October 1998 at SinoGenoMax.
SinoGenoMax participated in the International Human Genome Sequencing Project, and has been closely involved in several major genome-related research projects such as pathogenic microorganism sequencing projects, Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects.
Originally focused on DNA sequencing and analysis, SinoGenoMax has subsequently expanded its expertise in all aspects of molecular biology and protein biology. SinoGenoMax has built up several independent technical groups including genomics group, proteomics group, and molecular biology group. In particular, SinoGenoMax has perfected a rigorous quality-management system to implement process monitoring and quality control for all the procedures we perform. SinoGenoMax has passed the ISO 9001:2000 international certification of quality management system since 2004, and is now preparing to obtain ISO/IEC 17025:2005 accreditation of testing laboratory.
There are currently 100 employees working at SinoGenoMax located in Beijing Economic-Technological Development Area. SinoGenoMax’s 5,000 square meter laboratory building is fully equipped with top class facilities including DNA Sequencers, mass spectrometry, HPLC, Microarray Chip Reader, and lab automation workstation, for high throughput operation and analysis in genomics and proteomics research. A proprietary Laboratory Information Management System(LIMS) has been implemented for standardized management of samples,data and work flow, and all procedures are performed under the guidance of corresponding SOPs.
In the past few years, SinoGenoMax has successfully provided high quality and cost-effective services for several international pharmaceutical companies. Whether in the scientific research or industrial of production, the widely recognized achievements have enabled SinoGenoMax to become the best biotechnology service company at home and abroad.
Large-scale DNA sequencing, Bioinformatics, Protein expression & Purification, Protein Seperation & Identification, Antibody Production, Functional Genomics & Drug Disc. Platform, Genome-Based Target Validation, Pathway-Based Target Validation, siRNA-Based Drug Screening
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent…
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its strategically important China business. van Acker takes the helm against…
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation with Sanofi China’s Irene Deng, looks at how Chinese pharmaceutical regulations have evolved and…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach…
In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem. …
The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player…
Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen…
The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission…
See our Cookie Privacy Policy Here